ALPS Medical Breakthroughs ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
ALPS Medical Breakthroughs ETF SBIO
Morningstar’s Analysis SBIO
Will SBIO outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 30.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Veradermics Inc | 3.82 | 7M | Healthcare |
CG Oncology Inc | 3.69 | 7M | Healthcare |
Oruka Therapeutics Inc | 3.54 | 7M | Healthcare |
Travere Therapeutics Inc Ordinary Shares | 3.32 | 6M | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 3.19 | 6M | Healthcare |
Dianthus Therapeutics Inc | 2.92 | 6M | Healthcare |
Edgewise Therapeutics Inc | 2.88 | 5M | Healthcare |
Relay Therapeutics Inc Ordinary Shares | 2.70 | 5M | Healthcare |
Amylyx Pharmaceuticals Inc | 2.44 | 5M | Healthcare |
Xenon Pharmaceuticals Inc | 2.33 | 4M | Healthcare |